Science Corp., which was founded by Neuralink co-founder Max Hodak to develop a retina and brain implant system, raised $100M+ led by Khosla Ventures
Context & Ripple Effects
Science Corp. was created by Neuralink co-founder Max Hodak around retina and brain implants, placing this financing alongside Neuralink's own heavily funded brain-computer-interface effort, including its $280M Series D.
The round looks like an early step in a longer commercialization arc: Science later reported a $230M financing at a $1.5B valuation and subsequently won EU approval for its Prima bionic-eye system.
First-order effects
- Science Corp. receives more than $100M to fund development of its retina and brain implant system, while Khosla Ventures takes the lead-investor role.
- The financing gives Hodak's company a materially funded platform distinct from Neuralink, despite their shared founder connection.
Second-order effects
- Science Corp. becomes a better-capitalized contender for talent, clinical-development capacity and investor attention in implantable neurotechnology.
- The round establishes funding momentum that can support later, larger raises as the company moves its retinal program toward commercialization.
Third-order effects
- If repeat financing and regulatory progress continue, vision-restoration implants could form a more distinct commercial branch of neurotechnology rather than remaining secondary to general-purpose brain-computer interfaces.
- The pattern suggests that investors may increasingly differentiate implant companies by clinical use case and route to market, not solely by the breadth of their brain-interface ambitions.
The trend: Neurotechnology funding is increasingly following focused clinical implant programs from early development through regulatory and commercial milestones.